Skip to main content
OpenTrials
Completed

NCT Number: NCT05138562

TUC3PII-01_TU2670 Phase IIa Clinical Study

This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endometriosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

University Hospital Hradec Kralove, Hradec Králové, Hradec Kralove, Czechia

Loading trial locations.

About this study

Treatment Groups and Duration:

Following a washout period of up to 12 weeks, subjects will enter a screening period of up to 12 weeks including an observation period consisting of a complete menstrual cycle.

Subjects will be randomly assigned in a 1:1:1:1 ratio to receive either 12 weeks of TU2670 320 mg QD, TU2670 240 mg QD, TU2670 120 mg QD, or matching placebo. TU2670 or a matching placebo will be administered in the clinic on Day 1. Subjects in the PK subset population will also receive the following additional doses in the clinic: Day 2 (after collection of the 24-hour PK sample); the dose on the day scheduled for subsequent serial PK sample collection (Week 4 or Week 5); and the next scheduled dose (after collection of the 24-hour PK sample). All other doses can be taken by the subject at home. Following the end of treatment, subjects will be followed up for safety for 12 weeks.

Statistical Methods:

All formal statistical tests will be done at the 5% 2-sided significance level. Point estimates will have 2 sided 95% confidence intervals (CIs) where applicable.

Where appropriate, variables will be summarized descriptively (frequency and percent will be summarized for categorical variables; n (number of available subjects), mean, standard deviation [SD], median, minimum, and maximum will be presented for continuous variables) by study visit and by treatment group.

Statistical summaries will be presented for the changes from baseline to each time point in efficacy endpoints that it is applicable.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Independent Ethics Committee (IEC)-approved written informed consent/assent and privacy language as per national regulations must be voluntarily obtained from the subject.
  • Premenopausal female subject, 18 to 45 years, inclusive
  • Subject has moderate to severe endometriosis-related pain

Exclusion criteria

  • Subject has used hormonal contraceptives or other drugs with effects on gynecological endocrinology within 12 weeks
  • Subject has been nonresponsive to GnRH-agonist or antagonist therapy for the management of endometriosis.

Treatment and study plan

Placebo Comparator: Placebo

Drug

4 x placebo capsules, QD

Active Comparator: TU2670 320mg

Drug

320mg (80mg x 4), QD

Active Comparator: TU2670 240mg

Drug

240mg (80mg x 3 + placebo x 1), QD

Active Comparator: TU2670 120mg

Drug

120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD

Primary outcomes

  1. overall pelvic pain

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the mean dysmenorrhea score (defined as mean overall pelvic pain score on menstrual bleeding days) as measured by the Numeric Rating Scale(minimum 0, maximum 10, higher score mean a worse outcome) over the past month.

Secondary outcomes

  1. mean Numeric Rating Scale pain score

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) for non-menstrual pelvic pain (mean Numeric Rating Scale pain score on non menstrual bleeding days)

  2. mean overall pelvic pain Numeric Rating Scale pain score

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the mean overall pelvic pain Numeric Rating Scale pain score (mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) over all 28 days)

  3. mean Numeric Rating Scale dyspareunia score

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale((minimum 0, maximum 10, higher score mean a worse outcome) dyspareunia score

  4. rescue medication

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the use of protocol-defined rescue medication (ie, ibuprofen)

  5. Time to increase of dose of rescue medication

    Time frame: 12 weeks

    Time to increase of dose of rescue medication from 0 week to 12 weeks

  6. Time to decrease of dose of rescue medication

    Time frame: 12 weeks

    Time to decrease of dose of rescue medication from 0 week to 12 weeks

  7. Modified Biberoglu and Behrman sign and symptom scores

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the Modified Biberoglu and Behrman (mB&B) sign and symptom scores(minimum 0, maximum 3, higher score mean a worse outcome)

  8. Patient Global Impression of Change

    Time frame: 12 weeks

    Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome) at 12 weeks of treatment

  9. Endometriosis Health Profile-5

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment in the Endometriosis Health Profile-5 score(minimum 1(Never), maximum 5(Always), higher score mean a worse outcome)

  10. 36-Item Short Form Health Survey

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the 36-Item Short Form Health Survey(Scoring meaning is different from the questions but usually lower score mean a worse outcome)

  11. Work Productivity and Activity Impairment Questionnaire: General Health

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the Work Productivity and Activity Impairment Questionnaire: General Health (Scoring meaning is different from the questions)

Other outcomes

  1. Bone mineral density loss

    Time frame: 12 weeks

    Change from baseline to 12 weeks of treatment of the bone mineral density as assessed by dual-energy X-ray absorptiometry (DXA)

Sponsors and collaborators

Lead sponsor

TiumBio Co., Ltd.

Industry

Registry information

Official study title

A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects With Mod to Severe Endometriosis-Associated Pain

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Dec 1, 2021
Registry last updated
Aug 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.